ArticleDiscover oncology2026
Prognostic nomograms for predicting overall and cancer-specific survival in acute erythroid leukemia: a SEER-based study.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute erythroid leukemia (AEL) is a rare and highly aggressive subtype of acute myeloid leukemia with a poor prognosis and no standardized treatment strategy. Its rarity and molecular complexity mean that conventional staging systems fail to predict its outcomes accurately. This study aimed to develop and validate nomogram models for predicting overall survival (OS) and cancer-specific survival (CSS) in patients with AEL.
methodsWe retrospectively analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021) and identified 778 patients with AEL (ICD-O-3 code 9840/3). Patients were divided randomly into training (n = 544) and validation (n = 234) cohorts. Independent prognostic factors for OS and CSS were identified using Cox regression. Nomograms were developed and validated using concordance index (C-index), receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Risk stratification was performed based on nomogram-derived scores.
resultsMultivariate Cox regression identified age, chemotherapy, marital status, and first primary tumor status as independent prognostic factors for both OS and CSS. The nomograms demonstrated good discrimination, with C-index values of 0.669 (OS) and 0.665 (CSS) in the training cohort, and 0.654 (OS) and 0.661 (CSS) in the validation cohort. ROC analysis confirmed good predictive accuracy, and calibration plots showed good agreement between predicted and observed survival. DCA confirmed the clinical utility of the nomograms. Risk stratification based on median nomogram scores effectively distinguished between high- and low-risk patients (P < 0.001).
conclusionsWe developed and validated novel SEER-based nomograms for predicting OS and CSS in patients with AEL, which demonstrated reliable performance in internal validation. However, the lack of molecular data (e.g., TP53 mutations) limits the biological interpretability of the models. External validation is required before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.